Expectations of side effects evoked by perceptual characteristics of curatives and their psychological background;Tabletták perceptuális jellemzocombining double acute accenti által generált mellékhatás-elvárások és pszichológiai hátterük

Mentalhigiene es Pszichoszomatika

Volumn 10, Issue 1, 2009, Pages 47-62

  Köteles, Ferenc ^a   Bárdos, György ^a  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

Amplification; Expectations; Intelligent medicine designing; Nocebo; Non specific side effects; Optimism; Somatisation

Indexed keywords

EID: 63149182157     PISSN: 14198126     EISSN: 17863759     Source Type: Journal    
DOI: 10.1556/Mental.10.2009.1.3     Document Type: Review

References (55)

1. Aronson, K. R., Barrett, L. F., Quigleya, K. S. (2001): Feeling your body or feeling badly. Evidence for the limited validity of the Somatosensory Amplification Scale as an index of somatic sensitivity. Journal of Psychosomatic Research, 51: 387-394.
2. Bárdos Gy. (2003): Viselkedésélettan I: Pszichovegetatív kölcsönhatások. Scolar, Budapest.
3. Barsky, A. J. (1979): Patients who amplify bodily sensations. Annals of Internal Medicine, 91: 63-70.
4. Barsky, A. J. (1983): Nonpharmacologic aspects of medication. Archives of Internal Medicine, 143: 1544-1548.
5. Barsky, A. J., Goodson, J. D., Lane, R. S., Cleary, P. D. (1988): The amplification of somatic symptoms. Psychosomatic Medicine, 50: 510-519.
6. Barsky, A. J., Wyshak, G., Klerman, G. L. (1990): The Somatosensory Amplification Scale and its relationship to hypochondriasis. Journal of Psychiatric Research, 24: 323-334.
7. Benson, H., Epstein, M. D. (1975): The placebo effect: a neglected asset in the care of patients. Journal of the American Medical Association, 232: 1225-1227.
8. Benson, H., Friedman, R. (1996): Harnessing the power of the placebo effect and renaming it "remembered wellness". Annual Reviews of Medicine, 47: 193-199.
9. Bootzin, R. R., Bailey, E. T. (2005): Understanding placebo, nocebo, and iatrogenic treatment effects. Journal of Clinical Psychology, 61: 871-880.
10. Brody, H. (2000): The placebo response. Harper Collins, New York.
11. Brown, R. J. (2006): Medically unexplained symptoms: a new model. Psychiatry, 5: 43-47.
12. Casper, R. C., Tollefson, G. D., Nilsson, M. E. (2001): No gender differences in placebo responses of patients with major depressive disorder. Biological Psychiatry, 49: 158-160.
13. Cattaneo, A. D., Lucchelli, P. E., Filipucci, G. (1970): Sedative effects of placebo treatment. European Journal of Clinical Pharmacology, 3: 43-45.
14. Claridge, G. (1970): Drugs and human behaviour. Praeger Publishers, New York, Washington.
15. de Craen, A. J., Roos, P. J., Leonard de Vries, A., Keijnen, J. (1996): Effect of colour of drugs: systematic review of perceived effect of drugs and of their effectiveness. British Medical Journal, 313: 1624-1626.
16. Faul, F., Erdfelder, E., Lang, A.-G., Buchner, A. (2007): G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods, 39: 175-191.
17. Ferguson, J. M. (1993): Alprazolam XR: patient acceptability, safety, and tolerability. Psychiatric Annals, 23: 20-26.
18. Geers, A. L., Helfer, S. G., Kosbab, K., Weiland, P., Landry, S. J. (2005): Reconsidering the role of personality in placebo effects: Dispositional optimism, situational expectations, and the placebo response. Journal of Psychosomatic Research, 58: 121-127.
19. Geers, A. L., Kosbab, K., Helfer, S. G., Weiland, P., Wellman, J. A. (2007): Further evidence for individual differences in placebo responding: An interactionist perspective. Journal of Psychosomatic Research, 62: 563-570.
20. Glaser, E. M., Whittow, G. C. (1953): Evidence for a non-specific mechanism of habituation. Journal of Physiology, 122: 43P-44P.
21. Gliedman, L. H., Gantt, H. W., Teitelbaum, H. A. (1957): Some implications of conditional reflex studies for placebo research. American Journal of Psychiatry, 113: 1103-1107.
22. Gowdey, C. W., Hamilton, J. T., Philp, R. B. (1967): A controlled clinical trial using placebos in normal subjects: a teaching exercise. Canadian Medical Association Journal, 96: 1317-1322.
23. Green, D. M. (1962): Side effects. Federation Proceedings, 21: 179.
24. Green, D. M. (1964): Pre-existing conditions, placebo reactions, and "side effects". Annals of Internal Medicine, 60: 255-265.
25. Helman, C. G. (2001): Placebos and nocebos: the cultural construction of belief. In: Peters, D. (ed.): Understanding the placebo effect in complementary medicine. Churchill Livingstone, Edinburgh, 3-16.
26. Herzberg, P. Y., Glaesmer, H., Hoyer, J. (2006): Separating Optimism and Pessimism: A robust psychometric analysis of the revised life orientation test (LOT-R). Psychological Assessment, 18 (4): 433-438.
27. Keeley, R. (2002): When are medication side effects due to the nocebo phenomenon? Letter to the editor. Journal of the American Medical Association, 287 (19): 2503.
28. Kirsch, I. (1997): Specifying nonspecifics: psychological mechanisms of placebo effects. In: Harrington, A. (ed.): The placebo effect. An interdisciplinary exploration. Harvard University Press, Cambridge, 166-186.
29. Köteles F., Bárdos Gy. (2007): Tabletták várt hatása és színe/mérete közötti kapcsolatok. Mentálhigiéné és Pszichoszomatika, 8 (4): 277-290.
30. Köteles F., Bárdos Gy. (2008a): Placebo és személyiség - a primitívtocombining double acute accentl a megküzdocombining double acute accentig. I. A placebo-reszponder személyiség. Pszichológia, 28 (3): 267-285.
31. Köteles F., Bárdos Gy. (2008b): Placebo és személyiség - a primitívtocombining double acute accentl a megküzdocombining double acute accentig. II. Szituáció, emóció, motiváció, attribúció és megküzdés. Pszichológia, 28 (4): 339-356.
32. Köteles F., Bárdos Gy. (2009a): Nil nocere? A nocebo-jelenség. Magyar Pszichológiai Szemle, közlés alatt.
33. Köteles F., Bárdos Gy. (2009b): Gyógyszerek perceptuális jellemzocombining double acute accenti és potenciális hatásaik. Kézirat, közlésre benyújtva.
34. Kroenke, K. (2006): Physical symptom disorder: a simpler diagnostic category for somatization-spectrum conditions. Journal of Psychosomatic Research, 60: 335-339.
35. Kroenke, K., Spitzer, R. L., Williams, J. B. (2002): The PHQ-15: Validity of a new measure for evaluating the severity of somatic symptoms. Psychosomatic Medicine, 64: 258-266.
36. Moerman, D. E. (2002): Meaning, medicine and the "placebo effect". Cambridge University Press, Cambridge, 47-66.
37. Olshansky, B. (2007): Placebo and nocebo in cardiovascular health. Journal of the American College of Cardiology, 49: 415-421.
38. Pennebaker, J. W. (1982): The psychology of physical symptoms. Springer, New York
39. Pennebaker, J. W. (1994) Psychological bases of symptom reporting - perceptual and emotional aspects of chemical-sensitivity. Toxicology and Industrial Health, 10 (4-5): 497-511.
40. Rickels, K. (1965): Some comments on non-drug factors in psychiatric therapy. Psychosomatics, 6: 303-309.
41. Salavecz Gy., Neculai K., Rózsa S., Kopp M. (2006): Az erocombining double acute accentfeszítés-jutalom egyensúlytalanság kérdocombining double acute accentív magyar változatának megbízható sága és érvényessége. Mentá lhigiéné és Pszichoszomatika, 7 (3): 231-246.
42. Scheier, M. F., Carver, C. S., Bridges, M. W. (1994): Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): A re-evaluation of the Life Orien tation Test. Journal of Personality and Social Psychology, 67: 1063-1078.
43. Shapira, K., McClelland, H. A., Griffiths, M. R., Newell, D. J. (1970): Study on the effects of tablet colour in the treatment of anxiety states. British Medical Journal, 1970ii: 446-449.
44. Sipos K., Sipos M., Spielberger, C. D. (1994): A State-Trait Anxiety Inventory (STAI) magyar változata. In Mérei F., Szakács F. (szerk.): Pszichodiagnosztikai vademecum I/2. Nemzeti Tankönyvkiadó, Budapest, 123-148.
45. Spinhoven, P., van der Does, A. J. W. (1997): Somatization and somatosensory amplification in psychiatric outpatients: an explorative study. Comprehensive Psychiatry, 38 (2): 93-97.
46. Spriet, A., Spriet, C., Larousse, C., Chigot, D., Roux, M., Simon, P. (1977): Methodology and results of a survey of adverse reactions to a drug in privat practice. European Journal of Clinical Pharmacology, 11: 181-192.
47. Stauder A., Konkoly Thege B. (2006): Az észlelt stressz kérdocombining double acute accentív (PSS) magyar verziójának jellemzocombining double acute accenti. Mentálhigiéné és Pszichoszomatika 7(3): 203-216.
48. Ströhle, A. (2000): Increased response to a putative panicogenic nocebo administration in female patients with panic disorder. Journal of Psychiatric Research, 34: 439-442.
49. Szondy M. (2006): Optimizmus és egészség. Magyar Pszichológiai Szemle, 61 (4): 617-636.
50. Uhlenhuth, E., Alexander, P. E., Dempsey, G. M., Jones, W., Coleman, B. S., Swiontek, A. M. (1998): Medication side effects in anxious patients: Negative placebo responses? Journal of Affective Disorders, 47: 183-190.
51. Varga K., Dúll A., Gocombining double acute accentsiné Greguss A. (1992): Általános pszichológiai gyakorlatok I. Tankönyvkiadó, Budapest, 51-52.
52. Vautier, S., Raufaste, E. (2006): Configural instability of data from the Life Orientation Test-Revised. Personality and Individual Differences, 40: 1511-1519.
53. Vautier, S., Raufaste, E., Carious, M. (2003): Dimensionality of the Revised Life Orientation Test and the status of filler items. International Journal of Psychology, 38 (6): 390-400.
54. Whitehorn, J. C. (1958): Psychiatric implications of the "placebo effect." American Journal of Psychiatry, 114: 662-664.
55. Wolf, S. (1959): The pharmacology of placebos. Pharmacological Review, ii: 689-705.